Display options
Cite
Liu X, Niu N, Li P, et al. LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis. Cancer Cell Int. 2021;21(1):425doi: 10.1186/s12935-021-02115-3.
Liu, X., Niu, N., Li, P., Zhai, L., Xiao, K., Chen, W., & Zhuang, X. (2021). LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis. Cancer cell international, 21(1), 425. https://doi.org/10.1186/s12935-021-02115-3
Liu, Xiaojing, et al. "LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis." Cancer cell international vol. 21,1 (2021): 425. doi: https://doi.org/10.1186/s12935-021-02115-3
Liu X, Niu N, Li P, Zhai L, Xiao K, Chen W, Zhuang X. LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis. Cancer Cell Int. 2021 Aug 13;21(1):425. doi: 10.1186/s12935-021-02115-3. PMID: 34389018; PMCID: PMC8361654.
Copy Download .nbib Format: NLM
Share it on

Cancer Cell Int. 2021 Aug 13;21(1):425. doi: 10.1186/s12935-021-02115-3.

LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis.

Cancer cell international

Xiaojing Liu, Na Niu, Pibao Li, Liping Zhai, Ke Xiao, Wendan Chen, Xuewei Zhuang

Affiliations

  1. Department of Clinical Laboratory Medicine, Shandong University Qilu Hospital, Jinan, 250012, China.
  2. Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
  3. Intensive Care Unit, The Third Hospital of Shandong Province Affiliated To Shandong University, Jinan, 250041, China.
  4. Shandong Province Endemic Disease Control Institute, Jinan, 250014, China.
  5. Department of Clinical Laboratory Medicine, The Third Hospital of Shandong Province Affiliated To Shandong University, #12 Wuying Shan Zhong Road, Tianqiao District, Jinan, 250041, China. [email protected].

PMID: 34389018 PMCID: PMC8361654 DOI: 10.1186/s12935-021-02115-3

Abstract

BACKGROUND: Long noncoding RNAs (lncRNAs) OGFRP1 is up-regulated in endometrial cancer and cervical carcinoma, and OGFRP1 suppression inhibits the malignant behavior of cancer cells. Here, we evaluated the expression pattern, biological function and potential mechanism of OGFRP1 in non-small cell lung cancer (NSCLC).

METHODS: The expression of target genes in 25 pairs of clinically collected NSCLC and normal lung tissue samples was detected by qRT-PCR or western blot. We screened the siRNA (siOGFRP1) to down-regulate the expression of OGFRP1 in A549 and H1299 cells. The biological function of A549 and H1299 cells were examined by CCK8, wound healing and transwell assays. The molecular mechanism of OGFRP1 was further explored.

RESULTS: The expression of OGFRP1 in NSCLC tissues were higher than that in normal lung tissue. siOGFRP1 inhibited the proliferation, migration and invasion of A549 and H1299 cells. In addition, the expression of EMT-related and apoptosis-related proteins was changed by siOGFRP1 transfection. OGFRP1 can directly interact with miR-4640-5p, and siOGFRP1 increased the level of miR-4640-5p. Moreover, miR-4640-5p could directly bind to the 3' UTR region of eIF5A mRNA. eIF5A was highly expressed in NSCLC tissues, and predicted a poor prognosis. In addition, the expression of miR-4640-5p and eIF5A in NSCLC tissues were negatively correlated, while the expression of OGFRP1 and eIF5A were positively correlated. Knockdown of OGFRP1 inhibited the expression of eIF5A, while transfection of miR-4640-5p inhibitor up-regulated the expression of eIF5A.

CONCLUSIONS: Taken together, we demonstrated that down-regulation of OGFRP1 inhibited the progression of NSCLC through miR-4640-5p/eIF5A axis.

© 2021. The Author(s).

Keywords: NSCLC; Proliferation; eIF5A; lncRNA OGFRP1

References

  1. Genes Dev. 2011 Sep 15;25(18):1915-27 - PubMed
  2. Cell. 2013 Jul 3;154(1):26-46 - PubMed
  3. RNA. 2015 Dec;21(12):2007-22 - PubMed
  4. Pathologe. 2014 Nov;35 Suppl 2:188 - PubMed
  5. Oncol Rep. 2017 Dec;38(6):3481-3488 - PubMed
  6. Nature. 2012 Sep 6;489(7414):57-74 - PubMed
  7. Cancer Manag Res. 2018 Jul 02;10:1817-1826 - PubMed
  8. J Cell Biol. 2001 Mar 5;152(5):895-910 - PubMed
  9. Retrovirology. 2009 Oct 13;6:90 - PubMed
  10. Biochem Biophys Res Commun. 2016 Sep 16;478(2):811-7 - PubMed
  11. Cell Biochem Funct. 2019 Dec;37(8):591-597 - PubMed
  12. Biochem Biophys Res Commun. 2018 Oct 28;505(2):578-585 - PubMed
  13. Mutagenesis. 2005 Jul;20(4):255-69 - PubMed
  14. Nucleic Acids Res. 2013 May;41(9):4976-87 - PubMed
  15. Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):716-21 - PubMed
  16. CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 - PubMed
  17. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820905823 - PubMed
  18. Nature. 2009 May 7;459(7243):118-21 - PubMed
  19. Biochim Biophys Acta. 2016 Jan;1859(1):128-38 - PubMed
  20. Mol Cell. 2004 Nov 19;16(4):641-53 - PubMed
  21. Nat Rev Genet. 2009 Mar;10(3):155-9 - PubMed
  22. Exp Biol Med (Maywood). 2016 Mar;241(6):644-9 - PubMed
  23. Cell Signal. 2014 May;26(5):1098-104 - PubMed
  24. Cell Biol Int. 2019 Feb;43(2):158-166 - PubMed
  25. J Biol Chem. 2006 Nov 17;281(46):35336-46 - PubMed
  26. Biochim Biophys Acta. 2016 Jan;1859(1):16-22 - PubMed
  27. Mol Cancer. 2016 May 27;15(1):43 - PubMed
  28. Oncotarget. 2015 Sep 15;6(27):23582-93 - PubMed
  29. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2083-2090 - PubMed
  30. Curr Mol Med. 2007 Feb;7(1):3-14 - PubMed
  31. Cancers (Basel). 2015 Sep 09;7(3):1815-46 - PubMed
  32. Gastroenterology. 2014 Jun;146(7):1701-13.e9 - PubMed
  33. Tumour Biol. 2014 Aug;35(8):7935-44 - PubMed
  34. Biomed Pharmacother. 2017 Nov;95:331-338 - PubMed
  35. Math Biosci Eng. 2019 Dec 9;17(2):1593-1603 - PubMed
  36. Oncogene. 2011 Apr 21;30(16):1956-62 - PubMed
  37. EMBO Rep. 2017 Oct;18(10):1837-1853 - PubMed
  38. Genome Res. 2012 Sep;22(9):1760-74 - PubMed
  39. Cold Spring Harb Perspect Biol. 2014 Aug 01;6(8): - PubMed
  40. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6415-9 - PubMed
  41. Int J Mol Sci. 2017 Mar 29;18(4): - PubMed
  42. Blood. 2007 Feb 15;109(4):1701-11 - PubMed
  43. J Thorac Dis. 2013 Oct;5 Suppl 5:S479-90 - PubMed

Publication Types

Grant support